Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Real-time Estimate Cboe BZX  -  11:50 2022-12-02 am EST
36.99 USD   +2.32%
11/30Zai Lab : to Present Interim Overall Survival Results for ZEJULA« (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary
PU
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Sector news Biopharmaceuticals
09:44aUGI Says Talks to Sell French Energy Marketing Business Discontinued But Exit Still Pla..
MT
12/01Atlantic Equities Adjusts Price Target on Biogen to $295 From $220, Maintains Neutral R..
MT
12/01UBS Adjusts Biogen Price Target to $338 From $319, Maintains Buy Rating
MT
12/01Analyst recommendations: Biogen, BAT, Hubbell, Liberty Global, P..
MS
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Wall Street rallies after Powell eyes slower rate hikes
RE
11/30Wall Street rises after Powell eyes slower rate hikes
RE
11/30Global markets live: Apple, Tesla, Boeing, HP, Intuit...
MS
11/30Trending: Eisai/Biogen Alzheimer's Drug Shows Positive Results
DJ
11/30Stifel Adjusts Price Target on Biogen to $331 From $299, Maintains Buy Rating
MT
11/30Jefferies Adjusts Price Target on Biogen to $350 From $325, Maintains Buy Rating
MT
11/30Wedbush Raises Biogen's Price Target to $247 From $218, Says Data Reinforces Likelihood..
MT
11/30Barclays Raises Price Target on Biogen to $313 From $275, Keeps Equalweight Rating
MT
11/30Biogen, Eisai Say Lecanemab Reduces Clinical Decline in Early Alzheimer's Disease Phase..
MT
11/29Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus
RE
11/29Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial
RE
11/29Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
11/29Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheime..
MT
11/29(OFFICIAL)-UPDATE 2-Japanese drugmaker Eisai's shares drop on report of death in Alzhei..
RE
11/28Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial
DJ
11/28Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial
RE
11/28China Protests Spark Supply Concerns, Weighing on US Equities
MT
11/28China COVID Protests Spark Supply Chain Concerns, Weighing on US Equities
MT
11/28Sector Update: Health Care Weakening Near Monday Close
MT
11/28Sector Update: Health Care Stocks Drifting Lower Monday Afternoon
MT
11/28Sector Update: Health Care
MT
11/28China COVID-19 Protests Weigh on US Equity Traders' Sentiment
MT
11/28China COVID-19 Protests Weigh on US Equities as Sentiment Sours Amid Growth Worries
MT
11/28Growing China COVID-19 Protests Weigh on Equities Amid Growth Worries
MT
11/28Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
11/25WuXi Biologics Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executiv..
CI
11/23Wuxi Biologics Inc. Announces Appointments to Strategy Committee
CI
11/22UniQure's Hemophilia B Therapy Receives FDA Nod; Shares Rise in After-Hours Trade
MT
11/22CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B
CI
11/22Australia's CSL prices hemophilia gene therapy at $3.5 million
RE
11/22FDA approves CSL's gene therapy for hemophilia
RE
11/21Teva Pharmaceutical Names Richard Francis as President, CEO
DJ
11/21Teva hires ex-Novartis executive to succeed CEO Schultz
RE
11/20Australian shares inch higher on healthcare, banking boost
RE
11/17Australian shares snap losing streak as geopolitical tensions ease
RE
11/15Truist Securities Boosts Price Target on Biogen to $350 From $265, Maintains Buy Rating
MT
11/15Alexion Pharmaceuticals, Inc. completed the acquisi..
CI
11/14Wall Street ends lower as investors gauge Fed's policy path
RE
11/14S&P 500 falls as investors gauge Fed's policy path
RE
11/14Wall Street moves higher as investors gauge Fed's policy path
RE
11/14Oppenheimer Adjusts Biogen Price Target to $315 From $300, Maintains Outperform Rating
MT
11/14Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/11Guggenheim Raises Price Target on Biogen to $270 From $265, Maintains Neutral Rating
MT
11/10Biogen Names Christopher Viehbacher CEO
MT
11/10Biogen Inc. Announces Executive Changes
CI
11/10Biogen Inc. Announces Board and Executive Changes
CI
11/04U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents
RE
11/04U.S. flu hospitalizations highest in 10 years, officials say
RE
11/02Transcript : CSL Limited - Special Call
CI
11/02Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration
DJ
11/02Domestic share buyers step in as foreign funds flee China
RE
11/01Arcturus Up 26% After Hours on CSL Seqirus Vaccine Collaboration
DJ
11/01Australia's CSL in mRNA vaccine licensing deal with U.S.-based Arcturus
RE
11/01Australia's CSL in mRNA vaccine licensing deal with Arcturus
RE
11/01Mizuho Securities Raises Price Target on Biogen to $325 From $270, Keeps Buy Rating
MT
10/31Insider Sell: Biogen
MT
10/27Samsung Biologics's Net Income Declines in Q3
MT
10/26Goldman Sachs Upgrades Biogen to Buy From Neutral, Raises Price Target to $370 From $22..
MT
10/26UBS Adjusts Biogen Price Target to $319 From $309, Maintains Buy Rating
MT
10/26Canaccord Genuity Adjusts Biogen's Price Target to $325 From $285, Reiterates Buy Ratin..
MT
10/26Morgan Stanley Adjusts Price Target on Biogen to $325 From $321, Reiterates Overweight ..
MT
10/26Cowen Adjusts Biogen's Price Target to $300 From $270, Keeps Outperform Rating
MT
10/26Atlantic Equities Adjusts Biogen's Price Target to $220 From $200, Maintains Neutral Ra..
MT
10/26RBC Boosts Price Target on Biogen to $331 From $310 on Back of 'Solid' Commercial Perfo..
MT
10/26HC Wainwright Adjusts Biogen's Price Target to $325 From $240, Reiterates Buy Rating
MT
10/26Wedbush Raises Biogen's Price Target to $218 From $217, Maintains Neutral Rating
MT
10/26Biogen Inc. Announces New Data at ECTRIMS 2022 Highlight Company’s Commitment to A..
CI
10/26SVB Securities Adjusts Biogen's Price Target to $310 From $270, Keeps Outperform Rating
MT
10/26WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing..
CI
10/25Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
10/25Transcript : Biogen Inc., Q3 2022 Earnings Call, Oct 25, 2022
CI
10/25Biogen Posts Flat Q3 Adjusted Earnings, Revenue Decline; Raises FY2022 Guidance
MT
10/25Biogen confident in Alzheimer's drug ahead of rivals' data
RE
10/25Biogen sales fall 9.7% on Tecifdera competition
RE
10/25Biogen Inc. Revises Revenue Guidance for the Full Year 2022
CI
10/25Biogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
10/24Jefferies Raises Biogen's Price Target to $325 From $300, Maintains Buy Rating
MT
10/23WuXi Biologics Releases New cGMP Drug Product Manufacturing Facility to Support End-To-..
CI
10/21Australian shares end lower on hawkish U.S Fed narrative
RE
10/18Roche's Alzheimer's Disease Drug Candidate Put Under Spotlight After Q3 Sales Dip
MT
10/17Biogen Says US FDA Extends Fee Act for NDA for Tofersen by Three Months to April 25
MT
10/17U.S. health regulator extends review of Biogen's ALS drug
RE
10/17U.S. health regulator extends review of Biogen's ALS drug
RE
10/17Biogen Inc. Announces FDA's 3-Month Extension of Review Period for the New Drug Applica..
CI
10/17Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zur..
CI
10/17Biogen : FDA Extends Review of Tofersen in Rare Form of ALS
DJ
10/16Australia's CSL raises annual profit forecast on Swiss acquisition
RE
10/16Transcript : CSL Limited - Special Call
CI
10/14Guggenheim Adjusts Price Target for Biogen to $265 From $190, Maintains Neutral Rating
MT
10/13US Stocks Finish Higher Thursday as Investors Weigh Another Hot Inflation Reading
MT
10/13US Stocks Finish Higher Thursday as Investors Weigh Another Hot Inflation Reading
MT
10/13Sector Update: Health Care Rises with Broader Thursday Markets
MT
10/13Sector Update: Health Care Stocks Advancing in Broad-Based Markets Rally
MT
Upcoming event on ZAI LAB LIMITED